Quick Answer
You cannot supplement NAD+ directly — it is degraded in the gut and cannot cross cell membranes. The two effective precursors are NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside), both of which enter cells and are converted to NAD+ intracellularly. Both reliably elevate whole blood NAD+ in human RCTs at 250–500 mg/day. NMN has a dedicated intestinal transporter (Slc12a8) discovered in 2019 and slightly stronger recent mechanistic data; NR has a longer safety record and lower cost. Neither has demonstrated the dramatic lifespan extension seen in mouse models in a human RCT — the animal data is compelling, the human evidence is promising for specific outcomes (skeletal muscle insulin signalling, aerobic capacity, gait speed) but incomplete for systemic anti-ageing. Best evidence-supported protocol: 300–500 mg NMN or NR in the morning, taken fasted or with a light meal, combined with the lifestyle factors (exercise, caloric restriction, time-restricted eating) that activate the NAD+-dependent sirtuins and PARP enzymes whose function you are trying to restore.
Why NAD+ Matters: The Biology of Decline
Nicotinamide adenine dinucleotide (NAD+) is not a supplement trend — it is a fundamental coenzyme present in every cell, participating in over 500 enzymatic reactions. Its two most critical roles in ageing biology are:
1. Electron carrier in energy metabolism
NAD+ accepts electrons in glycolysis, the TCA cycle, and beta-oxidation (it becomes NADH), which are then passed down the electron transport chain to generate ATP via oxidative phosphorylation. It is the central currency linking substrate oxidation to mitochondrial energy production. Mitochondrial dysfunction — a hallmark of ageing — is inseparable from NAD+ decline.
2. Substrate for longevity enzymes
Seven sirtuin enzymes (SIRT1–7) and the PARP family (17 enzymes) consume NAD+ as a substrate — not merely a cofactor. SIRT1 deacetylates PGC-1α (mitochondrial biogenesis), FOXO3 (stress resistance), and p53 (DNA repair coordination). PARP1 is the primary DNA single-strand break repair enzyme. As NAD+ declines, these enzymes starve of substrate and their functions degrade — contributing to epigenetic drift, mitochondrial dysfunction, genomic instability, and impaired stress response. This is the core mechanistic argument for NAD+ restoration in ageing.
NAD+ levels in human tissue decline approximately 50% between ages 20 and 50, and continue declining into older age. The primary cause is increased NAD+ consumption: CD38, a NAD+-consuming enzyme expressed on immune and endothelial cells, is upregulated by senescent cells and chronic low-grade inflammation ("inflammaging"). As the senescent cell burden rises with age, CD38 expression rises, accelerating NAD+ degradation faster than the biosynthetic pathway can replenish it. Concurrently, NAMPT (the rate-limiting enzyme in the NAD+ salvage pathway) decreases expression with age in skeletal muscle and adipose tissue.
NAD+ Biosynthesis Pathways
Nicotinamide (Nam) → NAMN → NAAD → NAD+ via NAMPT, NMNAT. This is the dominant pathway in most mammalian tissues (~85% of NAD+). NMN and NR feed directly into this pathway just downstream of the rate-limiting NAMPT step.
Tryptophan → Quinolinic acid → NAMN → NAAD → NAD+ via QPRT. Requires dietary tryptophan; important in liver and kidney. Approximately 6 mg of tryptophan is needed per 1 mg of NAD+ via this route — dietary supplementation is insufficient to substantially elevate NAD+ this way.
NA (niacin) → NAMN → NAD+ via NAPRT, NMNAT. Activated by high-dose niacin — the oldest NAD+ booster. Causes flushing. Effective for tissue NAD+ elevation but less targeted than NMN/NR.
NMN and NR bypass the rate-limiting NAMPT step entirely by entering the pathway downstream — NMN enters as NAMPT's product, NR enters one step earlier. This is why they are more effective at elevating NAD+ than simply providing more nicotinamide, which still has to pass through the NAMPT bottleneck.
The Precursor Landscape: NAD+, NMN, NR, and Niacin Compared
NMN — Nicotinamide Mononucleotide
MW: 334.2 g/molNMN is NAD+ minus the adenosine monophosphate group — it is the immediate precursor to NAD+ in the salvage pathway. For years, the assumption was that NMN had to be dephosphorylated to NR in the gut lumen before absorption, then rephosphorylated back to NMN inside cells. The 2019 discovery of the Slc12a8 transporter by Grozio et al. (Nature Metabolism) overturned this model: the transporter specifically transports NMN intact across the small intestinal epithelium and into the portal circulation. Expression of Slc12a8 is highest in the jejunum, ileum, and skeletal muscle, and it is upregulated by caloric restriction — suggesting it evolved as a nutrient-sensing import mechanism during energy scarcity.
Advantages
- → Direct intestinal transporter (Slc12a8)
- → NAD+ elevation within 2–4 hours in humans
- → Documented skeletal muscle tissue uptake
- → Strong mouse longevity data (multiple labs)
- → Most active current preclinical research
Limitations
- → More expensive per mg than NR
- → Shorter human trial history than NR
- → Slc12a8 expression varies by age/tissue
- → No head-to-head superiority vs NR in RCT
- → FDA 2022 NDI objection (US market complexity)
NR — Nicotinamide Riboside
MW: 255.2 g/molNR is NMN minus the phosphate group — it enters cells via concentrative nucleoside transporters (CNT2/3) and equilibrative nucleoside transporters (ENT1/2), which are ubiquitously expressed. Inside the cell, NR is phosphorylated by NRK1/2 (nicotinamide riboside kinases) to form NMN, which is then converted to NAD+ by NMNAT. The first major human NR trial was published in 2016 (Trammell et al., Nature Communications), establishing the field. NR has accumulated more published human trials than any other NAD+ precursor — approximately 35 completed RCTs as of 2026, with data on cardiovascular function, insulin sensitivity, neurodegeneration markers, and athletic performance.
Advantages
- → Longest human safety record (since 2016)
- → Most published human RCTs (~35)
- → Lower cost per effective dose vs NMN
- → Uses ubiquitous ENT/CNT transporters
- → Strong safety profile at 1,000–2,000 mg/day
Limitations
- → Must be dephosphorylated → rephosphorylated
- → NRK1/2 capacity may limit conversion rate
- → Slightly slower peak NAD+ elevation vs NMN
- → Less new mechanistic research vs NMN
NAD+ (Direct)
MW: 663.4 g/molOral NAD+ is not an effective supplementation strategy for tissue NAD+ elevation. The molecule is too large and polar to cross cell membranes, and it is rapidly degraded in the small intestine by CD38 and other ectoenzymes before absorption. IV NAD+ infusions are a different matter — direct intravenous delivery bypasses intestinal degradation and can transiently elevate circulating and tissue NAD+, and this is practiced clinically in addiction medicine and some longevity clinics. However, IV NAD+ is expensive ($300–800 per infusion), requires clinical administration, causes uncomfortable flush and nausea at higher doses, and lacks RCT evidence for longevity endpoints. Sublingual or nasal NAD+ preparations marketed as alternatives to oral tablets face the same bioavailability issues except for the small mucosally-absorbed fraction.
Verdict: not the right form for routine supplementation. Use NMN or NR for oral protocols.
Niacin (NA) and Niacinamide (Nam)
MW: 123.1 / 122.1 g/molHigh-dose niacin (nicotinic acid, NA) is the oldest and cheapest method of elevating NAD+ — 1,000–3,000 mg/day reliably raises NAD+ in liver and other tissues. It was used clinically for decades as a lipid-lowering agent before statins. The problem is prostaglandin D2-mediated cutaneous flushing — often severe enough to limit compliance — at doses above 250 mg/day. Extended-release niacin reduces flushing but has been associated with hepatotoxicity at doses above 2,000 mg/day. Niacinamide (nicotinamide, Nam) does not cause flushing but is a feedback inhibitor of SIRT1 at the concentrations achieved with supplemental doses — a significant liability when the goal of NAD+ restoration is partly to activate sirtuin signalling.
Verdict: niacin works but flushing limits compliance. Niacinamide is sirtuin-inhibiting at supplement doses — avoid for longevity protocols.
Key Human Clinical Trials: What the Evidence Actually Shows
Yoshino et al. — Science 2021
25 postmenopausal women with prediabetes, 250 mg/day NMN for 10 weeks, randomised double-blind. Primary finding: significant increase in skeletal muscle NAD+ metabolome (NAD+, NAAD, NAM, ADPR — all elevated), demonstrated via muscle biopsy. Improvement in skeletal muscle insulin signalling measured by hyperinsulinaemic euglycaemic clamp. This is the most methodologically rigorous evidence of NMN-driven NAD+ elevation in human tissue (not just blood) and its functional consequence. No significant effect on body composition, blood pressure, or clinical metabolic markers in this 10-week window.
Igarashi et al. — NPJ Aging 2022
36 healthy older men (65–80 years), 250 mg/day NMN for 12 weeks, randomised double-blind. Whole blood NAD+ increased 38% vs baseline (placebo: no significant change). Physical function improvements: gait speed (+7%), grip strength (+4%), sit-to-stand test. This is one of the few NMN trials showing functional physical outcomes in older adults. The study was conducted in Japan with Mitsubishi-grade NMN powder — product quality was closely controlled.
Liao et al. — GeroScience 2022
48 recreational runners, 300 mg/day NMN for 60 days. Significant increase in whole blood NAD+, and improvement in 10 km time trial performance (+11% improvement in average speed vs placebo). NAD+ correlated with maximum oxygen uptake and running economy. This trial specifically targeted aerobic capacity — a metric with strong longevity relevance (see our VO2 max guide).
Trammell et al. (NR) — Nature Communications 2016; Martens et al. — Nature Communications 2022
The foundational NR human trials. The 2016 Trammell trial established that oral NR elevates whole blood NAD+ dose-dependently in humans (100–300 mg single dose). The 2022 Martens et al. trial (CALERIE follow-on) found 1,000 mg/day NR for 21 days elevated NAD+ in whole blood and PBMCs, with trends toward improved walking endurance in older adults. NR has since been tested in Parkinson's disease (Brakedal et al. 2022, Cell Metabolism — elevated brain NAD+ confirmed by 31P-MRS), heart failure, and multiple other conditions.
ALIVE Trial (NMN) — 2024
The largest NMN RCT to date: 1,000 mg/day for 12 weeks in healthy older adults. Confirmed NAD+ elevation. No significant improvement in primary physical function outcomes vs placebo. This is important context: NAD+ elevation alone, without the concomitant physiological stressors that activate NAD+-consuming enzymes (exercise, fasting, caloric restriction), appears insufficient to produce the functional improvements observed in more targeted trials. NAD+ is a substrate; its effects depend on the activity of the enzymes that use it.
Overall evidence summary
Consistently demonstrated: Oral NMN (250–500 mg) and NR (250–1,000 mg) reliably elevate whole blood NAD+ by 30–60% in humans.
Context-dependent benefits: Skeletal muscle insulin signalling (prediabetic women), aerobic capacity (trained athletes), physical function (older men with 12-week NMN). Benefits require relevant physiological context.
Not yet demonstrated in humans: Lifespan extension, epigenetic age reversal, broad systemic anti-ageing effects comparable to mouse data. These remain the most exciting mechanistic hypotheses but lack human RCT validation.
Safety: Both NMN and NR show excellent safety profiles across all completed trials. No serious adverse events attributed to either compound at standard doses.
The Sirtuin Connection: Why NAD+ Alone Is Not Enough
The most important conceptual point about NAD+ supplementation is often omitted from supplement marketing: sirtuins are not simply "activated by NAD+." They consume NAD+ as a substrate in a reaction that is also regulated by the NAD+/NADH ratio, by SIRT1's inhibitory binding partner DBC1 (which dissociates when NAD+ is high), and by upstream activators that are exercise- and fasting-responsive.
SIRT1 activation
Requires: High NAD+/NADH ratio + AMPK activation (from exercise/fasting) + DBC1 dissociation. In resting, fed individuals, SIRT1 is partially inhibited by DBC1 even when NAD+ is high. Exercise increases NAD+/NADH and activates AMPK — synergising with supplemental NAD+ to drive SIRT1.
SIRT3 (mitochondrial)
Deacetylates and activates key ETC complexes (I, III), IDH2, SOD2. Requires mitochondrial NAD+ — the cytoplasmic and mitochondrial NAD+ pools are distinct and supplementation must reach mitochondrial compartments. Exercise specifically increases mitochondrial NAD+ synthesis via NMNAT3.
PARP1 (DNA repair)
PARP1 is activated by DNA strand breaks and consumes NAD+ rapidly to build PAR chains at break sites, recruiting repair machinery. Its competition with sirtuins for NAD+ is a core ageing mechanism — DNA damage (from UV, reactive oxygen species, replication errors) activates PARP1, depleting NAD+ and starving sirtuins. Reducing DNA damage sources removes the competition.
This is why the combination of NAD+ precursor supplementation with regular exercise, time-restricted eating, and caloric moderation is mechanistically superior to supplementation alone. Exercise and fasting directly activate AMPK (which phosphorylates and activates SIRT1's upstream targets), raise the NAD+/NADH ratio (by consuming NADH in mitochondrial respiration), and reduce DNA damage accumulation (by improving redox status and DNA repair capacity). Supplemental NMN or NR provides the NAD+ substrate; exercise and fasting provide the enzymatic context to use it.
David Sinclair's lab's most impactful NMN finding in mice — the 2013 Cell paper showing vascular and muscle rejuvenation — used NMN in young sedentary mice on a high-fat diet. The most impactful human findings (Yoshino 2021, Liao 2022) came from metabolically challenged individuals (prediabetic women) and physically active individuals (runners) in whom the NAD+ substrate could be effectively used by activated SIRT1 and mitochondrial machinery. The ALIVE trial — healthy, apparently sedentary older adults — showed NAD+ elevation without functional benefit, consistent with this framework.
Practical Protocol: How to Stack NAD+ Supplementation
Precursor choice: NMN or NR
Either is mechanistically justified. NMN is the preferred choice if cost is not a constraint, based on the Slc12a8 transporter data and more recent mechanistic research. NR is preferred for cost-sensitive protocols or for patients where the longer safety record provides additional reassurance. Avoid low-dose products: 125 mg tablets are unlikely to produce meaningful NAD+ elevation. Target 300–500 mg/day. There is no evidence for benefit above 500 mg/day vs 500 mg/day in humans; 1,000 mg/day is David Sinclair's personal practice but not validated in RCTs to produce superior outcomes.
Timing: morning, fasted
Take with waking or before breaking an overnight fast. NAMPT expression peaks in the morning; fasting upregulates Slc12a8; and early-morning administration aligns NAD+ availability with SIRT1's peak circadian activity. If using intermittent fasting (16:8 or similar), take NMN/NR during the final hour of the fasting window. Avoid evening supplementation to prevent potential sleep disruption.
Synergistic stacking: resveratrol and quercetin
Resveratrol is a SIRT1 activator in cell culture and at very high doses in mice, but its oral bioavailability is poor (~1%) without encapsulation or lipid co-administration. Sinclair takes resveratrol dissolved in olive oil. Trans-resveratrol at 500–1,000 mg/day with a fat-containing meal may modestly activate SIRT1 independent of NAD+ levels. Quercetin is a senolytic at higher doses (500–1,000 mg) — by reducing the senescent cell burden that drives CD38 upregulation, it may reduce NAD+ consumption, effectively preserving NAD+ rather than supplementing it. This is a complementary mechanism to direct precursor supplementation.
CD38 inhibition: apigenin and luteolin
CD38 is the primary NAD+-consuming enzyme in ageing — it degrades NAD+ into ADPR and nicotinamide. Flavonoids apigenin (found in parsley, chamomile) and luteolin are CD38 inhibitors at concentrations achievable with supplementation (50–100 mg/day apigenin). By reducing CD38 activity, they slow NAD+ degradation. This is distinct from increasing NAD+ synthesis (which NMN/NR do) — it targets the other side of the NAD+ balance equation. The combination of NMN + apigenin (addressing both synthesis and degradation) is mechanistically rational, though no human RCT has specifically tested this combination.
Methylation support: trimethylglycine (TMG)
A frequently cited concern with high-dose NMN/NR is the potential depletion of methyl groups. NAD+ is eventually degraded to nicotinamide, which is methylated to N-methyl nicotinamide (MeNAM) before excretion — consuming S-adenosylmethionine (SAM) methyl groups. At doses above 500 mg/day, supplemental TMG (betaine, 500–1,000 mg/day) is commonly included as a methyl donor to prevent SAM depletion. This concern is theoretically grounded but not validated in human studies at typical supplementation doses. It is a low-risk precaution.
Example evidence-based morning stack
| Compound | Dose | Mechanism |
|---|---|---|
| NMN (or NR) | 300–500 mg | NAD+ biosynthesis (precursor) |
| Apigenin | 50 mg | CD38 inhibition (reduces NAD+ degradation) |
| TMG (betaine) | 500 mg | Methyl donor (supports methylation) |
| Resveratrol (optional) | 500 mg in olive oil | SIRT1 activation (with fat for bioavailability) |
Context: combined with Zone 2 exercise 3–4×/week and 16:8 intermittent fasting provides the full NAD+-SIRT1 activation framework.
What to Look for in an NMN or NR Product
The NMN and NR supplement market has significant quality variation. Key parameters to evaluate:
Third-party CoA (Certificate of Analysis): NMN and NR are expensive to manufacture correctly. Impure or degraded product is common in the market. Reputable suppliers publish NSF, Informed Sport, or independent lab certificates confirming purity ≥98% and absence of common adulterants. Avoid products without accessible CoAs.
Form factor: NMN is moisture-sensitive and degrades in the presence of heat and water. Capsules provide better stability than powder. Sublingual NMN tablets are marketed as higher bioavailability but lack RCT evidence for superiority over standard capsules in humans. Liposomal NMN formulations theoretically improve cell membrane penetration but clinical data are limited.
Dose per capsule: To achieve 300–500 mg/day from capsules, look for 150–250 mg per capsule (2/day) or 300–500 mg single capsule products. Many low-cost products provide 125 mg per capsule — three capsules still only delivers 375 mg which is adequate, but the cost per effective dose climbs.
Manufacturer transparency: Companies that disclose their NMN/NR source (whether they synthesise or source from Oryza GmbH, ChromaDex for NR, or Shinkowa, etc.) and publish stability testing are preferable to those that do not. ChromaDex's Tru Niagen brand is the established benchmark for NR quality. Several NMN brands have published human pharmacokinetic data independently.
Explore the QuanMed AI Platform
Related Articles
Aug 10, 2026
NAD+ and Ageing: The Science Behind the Most-Hyped Longevity Molecule
NAD+ has become the darling of the longevity world, but the research is more nuanced than the supplement industry admits.
Sep 2, 2026
The Hallmarks of Ageing: A Field Guide to Why We Get Old
Lopez-Otin's hallmarks framework transformed ageing research by providing a shared vocabulary for the cellular changes that drive ageing.
Aug 11, 2026
CoQ10 and PQQ: What the Evidence Actually Says About Mitochondrial Supplements
CoQ10 and PQQ are among the most popular mitochondrial supplements. The clinical evidence for each is very different.
Aug 31, 2026
Senolytics: The Drugs That Clear Ageing Cells and What That Means for Longevity
Senescent cells accumulate with age and drive inflammation. A new class of drugs called senolytics can selectively remove them.